Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

China

Guangdong Provincial People's Hospital, Guangzhou, Guangdong

Zhongnan Hospital of Wuhan University, Wuhan, Hubei

Hunan Cancer Hospital, Changsha, Hunan

Jiangsu Province Hospital, Nanjing, Jiangsu

Shandong Cancer Hospital, Jinan, Shandong

Linyi Cancer Hospital, Linyi, Shandong

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Beijing Cancer Hospital, Beijing

The First Medical Center, Chinese PLA General Hospital, Beijing

Southwest Hospital, Chongqing

Fudan University Shanghai Cancer Center, Shanghai

Tianjin Medical University Cancer Institute & Hospital, Tianjin